Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
Status:
Unknown status
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter study is to examine whether the proposed randomized treatment
regime results in a significantly longer survival time and higher quality of life than any
additionally applied multiple chemotherapy according to the CVD- scheme. So far neither
established treatment regimes nor reliable data exist for the second-line chemotherapy of
metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple
chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not
only a higher toxicity but show rarely a response rate higher than 10%.